Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134043 | 1.00 | ABCB1 (0.39) | ABCB1HDAC6 | |
| SCHEMBL30932702 | 1.00 | ABCB1 (0.39) | ABCB1HDAC6 | |
| SCHEMBL17520705 | 0.92 | ABCB1 (0.35) | ABCB1HDAC6 | |
| SCHEMBL17520671 | 0.86 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL17520691 | 0.86 | ABCB1 (0.37) | ABCB1HDAC6 | |
| SCHEMBL17520706 | 0.85 | ABCB1 (0.53) | ABCB1HDAC6 | |
| SCHEMBL17520687 | 0.85 | ABCB1 (0.53) | ABCB1HDAC6 | |
| SCHEMBL17520513 | 0.82 | ABCB1 (0.39) | ABCB1 | |
| SCHEMBL17520709 | 0.76 | ABCB1 (0.45) | ABCB1HDAC6 | |
| SCHEMBL17520693 | 0.76 | ABCB1 (0.49) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106434718-B | Method for obtaining non-ribosomal polypeptide active product | 杭州唯铂莱生物科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240174718-A1 | RYANODINE RECEPTOR INHIBITOR COMPOUNDS AND METHODS RELATING THERETO | VANDERBILT UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-10738316-B2 | Process for producing chimeric cyclooligodepsipeptides in filamentous fungi | Technische Universität Berlin (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-2812005-B1 | POLYHYDROXYLATED PENTACYCLIC TRITERPENE ACIDS AS HMG-COA REDUCTASE INHIBITORS | PRAIRIE BERRY EUROPE GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3119900-B1 | METHOD FOR OBTAINING NONRIBOSOMAL PEPTIDES BY HETEROLOGOUS EXPRESSION OF AT LEAST ONE NONRIBOSOMAL PEPTIDE SYNTHETASE IN ASPERGILLUS NIGER | UNIV BERLIN TECH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-20170137832-A1 | PROCESS FOR PRODUCING CHIMERIC CYCLOOLIGODEPSIPEPTIDES IN FILAMENTOUS FUNGI | TECHNISCHE UNIVERSITAET BERLIN (DE) | 2017-05-18 | — | — | US | disclosed |
| CN-106434718-A | Non ribosomal polypeptide active product capturing method | 杭州唯铂莱生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3119900-A2 | METHOD FOR OBTAINING MICROBIAL SECONDARY METABOLITES OR DERIVATIVES THEREOF BY HETEROLOGOUS EXPRESSION OF AT LEAST ONE SYNTHETASE OF SAID SECONDARY METABOLITES IN FILAMENTOUS FUNGI | Technische Universität Berlin (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2509967-B1 | NOVEL 24-MEMBERED CYCLOOCTADEPSIPEPTIDES FROM FUNGAL STRAINS AND THEIR USE AS ANTHELMINTICS OR ENDOPARASITICIDES | BAYER IP GMBH (DE) | 2016-02-17 | — | — | EP | disclosed |
| WO-2015140315-A2 | METHOD FOR OBTAINING MICROBIAL SECONDARY METABOLITES OR DERIVATIVES THEREOF BY HETEROLOGOUS EXPRESSION OF AT LEAST ONE SYNTHETASE OF SAID SECONDARY METABOLITES IN FILAMENTOUS FUNGI | Technische Universität Berlin (DE) | 2015-09-24 | — | — | WO | disclosed |
| US-20130237415-A1 | SAFENER COMPOSITIONS AND METHODS FOR REDUCING MYCOTOXINS | SYNGENTA CROP PROTECTION LLC (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2592931-A1 | SAFENER COMPOSITIONS AND METHODS FOR REDUCING MYCOTOXINS | Syngenta Participations AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20120302496-A1 | NOVEL 24-MEMBERED CYCLOOCTADEPSIPEPTIDES FROM FUNGAL STRAINS AND THEIR USE AS ANTHELMINTICS OR ENDOPARASITICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| EP-2509967-A1 | NOVEL 24-MEMBERED CYCLOOCTADEPSIPEPTIDES FROM FUNGAL STRAINS AND THEIR USE AS ANTHELMINTICS OR ENDOPARASITICIDES | Bayer Intellectual Property GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012021250-A1 | SAFENER COMPOSITIONS AND METHODS FOR REDUCING MYCOTOXINS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011069995-A1 | NOVEL 24-MEMBERED CYCLOOCTADEPSIPEPTIDES FROM FUNGAL STRAINS AND THEIR USE AS ANTHELMINTICS OR ENDOPARASITICIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| US-20080167444-A1 | Abc Transporter Inhibitor | SUNTORY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1721901-A1 | ABC TRANSPORTER INHIBITOR | SUNTORY LIMITED (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-5747448-A | ANTHELMINTICS | MEIJI SEIKA KAISHA, LTD. (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0685469-A1 | PF1022 DERIVATIVE, CYCLIC DEPSIPEPTIDE | MEIJI SEIKA KAISHA LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174718-A1 | RYANODINE RECEPTOR INHIBITOR COMPOUNDS AND METHODS RELATING THERETO | RYR2, RYR1, ATP2A2 | ABCB1 888/4885HDAC6 4012/4885 |
| US-20120302496-A1 | NOVEL 24-MEMBERED CYCLOOCTADEPSIPEPTIDES FROM FUNGAL STRAINS AND THEIR USE AS ANTHELMINTICS OR ENDOPARASITICIDES | TOP2B, XRN2, LONP1 | ABCB1 257/4885HDAC6 1813/4885 |
| US-20080167444-A1 | Abc Transporter Inhibitor | SLC47A1, ABCC1, SLC47A2 | ABCB1 4/4885HDAC6 2023/4885 |
| US-10738316-B2 | Process for producing chimeric cyclooligodepsipeptides in filamentous fungi | COASY, ERG28, FDPS | ABCB1 4107/4885HDAC6 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.